ALX Oncology Holdings Inc. announced that Jason Lettmann, a member of the Board of Directors, will succeed Jaume Pons, Ph.D. as Chief Executive Officer, effective September 6, 2023. Jason Lettmann has been involved with ALX Oncology for nearly a decade since its founding, having co-led the Company?s first institutional financing and serving as a member of the Company?s Board of Directors since 2015. Jason brings to the Chief Executive Officer post a broad suite of expertise relevant to ALX Oncology at its current stage of development including serving as Chief Executive Officer of Promedior Inc., a biotechnology company developing targeted medicines to treat fibrosis.

During his tenure, Promedior was acquired by Roche in 2020 for up to $1.39 billion. He also has extensive experience as an institutional healthcare investor at Lightstone Ventures from its inception in 2012 to July 2023 having served as a General Partner, and a General Partner at Morgenthaler Ventures, a venture capital and private equity firm, since June 2009, and as Vice President at Split Rock Partners, a venture capital firm, from June 2006 to June 2009. Mr. Lettmann has been a member of the Board of Directors of several public and privately held companies and involved in numerous successful exits including Ra Pharmaceuticals, a clinical-stage pharmaceutical company acquired by UCB.

Mr. Lettmann holds a B.A. from the University of Iowa and an M.B.A. from the University of Michigan?s Ross School of Business.